Bringing together one of the largest academic groups of addictions clinicians, educators and scientists in North America, the Addiction Division at CAMH conducts a broad range of translational and clinical research in the areas of alcohol, cannabis, tobacco, opioids, gambling and concurrent disorders. Work in these areas is conducted using state-of-the-art psychopharmacological, behavioural, neuroimaging, neurocognitive and genetic studies.
No Wrong Door
About 60 per cent of patients who come to CAMH have concurrent mental health and substance use disorders. By integrating care, patients can get help on their own terms—there’s no wrong door. Whether they come to a schizophrenia or child-adolescent clinic, their addiction will also be addressed, and the care they receive will be more effective overall.
Addiction is a complex disorder that involves the interaction of environmental factors with multiple genetic factors believed to increase the susceptibility of an individual to engage in addictive behaviour. Researchers within the Addictions Division are working to better understand and translate this knowledge into better treatments on a number of fronts:
Brain stimulation (rTMS) treatment for cannabis use and cognitive problems in people with schizophrenia
Randomized controlled trial on treatments for opioid use disorder
Risks and protective factors associated with substance use consumption
Gambling prevention and treatment initiatives in Northern Ontario
Mobile assessments of real-life alcohol and cannabis use
Biological factors associated with cannabis withdrawal (using genetics, brain imaging)
Effectiveness of free nicotine replacement therapy on Ontario smokers
For more information about our work and projects, please contact Division Coordinator, Danica Furtado-Fernandes.